TEVAR十年经验:胸主动脉瘤囊重塑与再干预结局
该回顾性研究纳入2004至2018年219例因孤立性降主动脉瘤行TEVAR的患者,评估中长期主动脉重塑与再干预需求。80%患者瘤囊稳定或缩小,内漏是瘤囊增长和死亡的预测因素,严格监测和再干预对预防主动脉事件必要。
要点
- TEVAR术后80%患者瘤囊稳定或缩小,与生存获益相关。
- 内漏是瘤囊增长(OR 65)和死亡(HR 3.6)的显著预测因素。
- 移植物oversizing百分比是再干预和死亡的保护因素,但>30%增加死亡风险。
核心结论
- 多数患者(80%)TEVAR术后瘤囊稳定或缩小,具有明确生存优势。
- 内漏预测瘤囊增长并增加死亡风险,需严格监测和再干预以预防主动脉事件。
研究设计与样本
- 机构回顾性综述,纳入2004至2018年因孤立性降主动脉瘤行TEVAR的219例患者。
- 主要结局包括瘤囊重塑、免于再干预和全因死亡率;其他结局包括内漏率、神经并发症率和总体术后并发症率。
主要发现
- TEVAR对瘤囊直径的中位效应为缩小0.7 cm(IQR -1.4至0.0 cm)。
- 80%(n=147)患者出现瘤囊缩小或稳定;围术期神经并发症发生率为16%(n=34)。
- 瘤囊增长的显著预测因素包括内漏(OR 65,P<.001)、术前颈动脉-锁骨下动脉搭桥(OR 8,P=.003)和移植物oversizing<20%(OR 15,P=.046)。
- 近端TEVAR锚定区主动脉直径每增加1 mm,内漏 odds 增加(OR 2,P=.049)。
- 再干预的显著预测因素包括入路并发症(OR 8)和锁骨下动脉覆盖(OR 6),而移植物oversizing每增加1%对再干预有保护作用(OR 0.005)。
关键数值与推荐
- 中位随访总生存率为78%(71%-83%)。
- 3年生存率:瘤囊稳定或缩小者为88%(80%-93%),瘤囊增长者为70%(49%-84%)(P=.0402)。
- Cox模型显示移植物oversizing每增加1%对死亡的保护HR<.001(P=.032),但oversizing>30%增加死亡风险HR>10(P=.049)。
- 死亡风险增加的因素包括内漏(HR 3.6,P=.033)、糖尿病(HR 4.1,P=.048)、年龄每增1岁(HR 1.2,P=.002)、手术年份每增1年(HR 1.3,P=.012)和外周动脉疾病(HR 5.2,P=.041)。
临床怎么用
- TEVAR术后应严格监测内漏,因其预测瘤囊增长和死亡风险。
- 再干预策略需关注入路并发症和锁骨下动脉覆盖,并优化移植物oversizing(避免<20%和>30%)。
- 瘤囊增长患者生存率较低,需加强随访和及时再干预。
局限性
- 回顾性单中心设计可能限制普遍性。
- 研究仅纳入孤立性降主动脉瘤,结论可能不适用于其他胸主动脉病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) results have been studied in short-term time frames. This study aimed to evaluate midterm and long-term outcomes of TEVAR, emphasizing postoperative aortic remodeling and need for reintervention. METHODS: This is an institutional retrospective review of TEVAR for isolated descending thoracic aortic aneurysms. Data were collected from 2004 to 2018. Primary outcomes studied included aneurysm sac remodeling, freedom from reintervention, and all-cause mortality. Other outcomes studied include endoleak rates, neurologic complication rates, and any overall postoperative complication rates. RESULTS: During the study period, 219 patients underwent TEVAR for descending thoracic aortic aneurysms. The median effect of TEVAR on sac diameter was a 0.7-cm decrease in size (interquartile range, -1.4 to 0.0 cm). During the study period, 80% (n = 147) of patients experienced aneurysm sac regression or stability. Perioperative neurologic complications occurred in 16% (n = 34) of patients. Significant predictors of sac growth were endoleak (odds ratio [OR], 65; P < .001), preoperative carotid-subclavian bypass (OR, 8; P = .003), and graft oversizing <20% (OR, 15; P = .046). Every 1-mm increase in aortic diameter at the proximal TEVAR landing zone led to an increased odds of endoleak (OR, 2; P = .049). Access complications (OR, 8) and subclavian artery coverage (OR, 6) significantly increased the odds of reintervention, whereas every percentage of graft oversizing protected against reintervention (OR, 0.005). Life-table analysis revealed an overall survival of 78% (71%-83%) at median follow-up. At 3 years, survival was 88% (80%-93%) for those with aneurysm sac stability or regression, whereas it was 70% (49%-84%) for those with aneurysm sac growth (P = .0402). Cox proportional hazards model showed that the only protective factor for mortality was percentage oversizing, with every 1% of oversizing having a hazard ratio (HR) of <.001 (P = .032). This was counterbalanced by the fact that patients with graft oversizing >30% had an increased odds of mortality with HR >10 (P = .049). Other significant factors that increased the odds of mortality included endoleak (HR, 3.6; P = .033), diabetes (HR, 4.1; P = .048), age (every 1-year increase in age; HR, 1.2; P = .002), year of surgery (every year subsequent to 2004; HR, 1.3; P = .012), and peripheral artery disease (HR, 5.2; P = .041). CONCLUSIONS: The majority of patients (80%) experience sac stability or regression after TEVAR, which offers a clear survival advantage. Endoleaks are predictive of sac growth, conferring increased mortality. Rigorous surveillance is necessary to prevent future aortic events through reintervention.
引用
- Tanious A, Boitano L, Canha L, et al. Thoracic aortic remodeling with endografting after a decade of thoracic endovascular aortic repair experience. J Vasc Surg. 2020. PMID: 32707385. doi:10.1016/j.jvs.2020.06.120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。